Multi-Purpose Active Pharmaceutical Ingredient Manufacturing Facility

Project Overview

A consortium led by an Indian pharmaceutical major and an Indian-European chemistry technology partner engaged IMARC Engineering to establish a greenfield multi-purpose Active Pharmaceutical Ingredient (API) manufacturing facility within the Visakhapatnam Bulk Drug Park in Andhra Pradesh — one of the three Bulk Drug Parks approved by the Government of India under the INR 3,000 Crore Bulk Drug Park scheme. Driven by India's well-documented 68 to 70 percent import dependence on APIs and Key Starting Materials (KSMs) — concentrated overwhelmingly with Chinese suppliers — and the Production Linked Incentive scheme for Bulk Drugs (an INR 6,940 Crore corpus covering 41 critical APIs and KSMs), the client identified a strategic opportunity to localise production of high-volume, hard-currency-earning APIs across cardiovascular, anti-infective, anti-diabetic, and CNS therapeutic categories where Indian formulators currently rely on imported KSMs for finished dosage manufacture.

The project involved establishing a 480 MT per annum multi-purpose facility producing 12 PLI-listed APIs and KSMs across six production blocks, with site infrastructure designed for Phase 2 expansion adding a dedicated penicillin G fermentation line and a vitamin synthesis facility.

Client's Challenges

The client faced several specific challenges in establishing greenfield multi-purpose API manufacturing in India:

• Multi-purpose chemistry complexity: Engineering production blocks capable of campaign-based manufacture of 12 distinct APIs and KSMs across organic, organometallic, and chiral chemistry routes, with cross-contamination prevention through dedicated trains, validated clean-in-place protocols, and disciplined material-flow segregation.
• Multi-Authority regulatory readiness: Simultaneous compliance with USFDA cGMP, EU EMA Ph. Eur. standards, WHO Prequalification, and Indian CDSCO requirements — with non-overlapping nuances on data integrity, supplier qualification, and validation rigour expected by each authority.
• PLI scheme compliance: Meeting the PLI Bulk Drugs scheme's Domestic Value Addition milestones and the per-API production milestone structure (with different scheme tiers for fermentation-based, chemically-synthesised, vitamin, and hormone categories) over the six-year scheme tenure.
• China KSM dependence reversal: Designing upstream synthesis steps to substitute KSM intermediates that have historically been imported from China — a deeper-localisation challenge than producing finished APIs from imported KSMs, and central to the PLI scheme's strategic intent.
• Solvent and effluent management: Operating in a coastal industrial corridor with strict Andhra Pradesh Pollution Control Board norms, requiring zero-liquid-discharge engineering, solvent recovery above 90 percent, and closed-loop systems for methylene chloride, methanol, toluene, and other process solvents.
• Workforce scarcity for cGMP API operations: Recruiting 1,260 personnel including 84 process chemists and 92 quality and regulatory affairs specialists in a regional location with limited prior USFDA-grade API operating experience, requiring structured partnerships with Indian universities and senior-hire programmes.

What We Did

• Pre-Investment and Strategic Advisory

Our feasibility study evaluated four candidate Indian locations — Visakhapatnam Bulk Drug Park (Andhra Pradesh), Hyderabad/Jadcherla pharma corridor (Telangana), Ankleshwar (Gujarat), and Bharuch (Gujarat) — against 16 weighted criteria including Bulk Drug Park common infrastructure benefits, raw material and solvent ecosystem proximity, port access for KSM imports and finished API exports, USFDA inspection history of the regional pharma cluster, and skilled chemistry-graduate engineering pipelines. Visakhapatnam Bulk Drug Park was selected on the strength of its Government of India-approved Bulk Drug Park status carrying capital subsidy of 75 percent of common infrastructure investment (capped at INR 200 Crore), shared steam, power, water and effluent treatment infrastructure, dedicated 220 kV grid feed, Adani Gangavaram Port proximity for solvent and KSM imports, and access to Andhra University and IIT Tirupati engineering and chemistry graduates.

CapEx planning of INR 1,920 Crore covered the six campaign production blocks, hydrogenation and high-pressure reaction facilities, solvent recovery and effluent treatment infrastructure, quality control and microbiology laboratories, warehouse and packaging, and the Bulk Drug Park common-utilities interface. Our team led the PLI Bulk Drugs scheme bid preparation that secured allocation across multiple API categories under the Drugs of Chemical Synthesis route, alongside Andhra Pradesh Industrial Infrastructure Corporation (APIIC) land allotment, AP Bulk Drug Park capital subsidy structuring, electricity duty exemption advisory, and Central Drugs Standard Control Organisation (CDSCO) pre-application engagement. Financial modelling demonstrated post-tax IRR of 21.6 percent at full ramp with a 5.4-year payback inclusive of PLI accruals and AP Bulk Drug Park capital subsidy.

• Engineering and Design Services

IMARC designed a 48,000 sq.m built-up facility on a 28-hectare site comprising six campaign production blocks, each engineered for grade-level cross-contamination prevention: Block 1 for cardiovascular APIs, Block 2 for anti-infective APIs, Block 3 for anti-diabetic APIs, Block 4 for CNS APIs, Block 5 for shared KSM and intermediate synthesis, and Block 6 for hydrogenation and high-pressure reactions operating up to 50 bar. Reactor inventories spanned 300 L jacketed glass-lined vessels through to 12,000 L production reactors, with associated centrifuges, agitated nutsche filter dryers, fluidised bed dryers, and milling equipment matched to each block's product chemistry.

Solvent management was engineered as a closed-loop system across the entire facility: multi-effect distillation recovery achieving 94 percent solvent recovery across methylene chloride, methanol, toluene, ethyl acetate, and isopropanol streams; dedicated condensation and storage infrastructure preventing cross-contamination between blocks; and continuous emission monitoring on all vents. Effluent treatment was engineered for zero-liquid-discharge through multi-effect evaporators, mechanical vapour recompression, and salt crystallisation, with final treated water reused as cooling tower make-up. Utility design covered 18 MW of contracted demand supplemented by 4 MW dedicated solar generation, integration with the Bulk Drug Park's common steam supply at 18 bar, captive 99.9 percent purity nitrogen at 480 Nm³/hr, Purified Water generation at 60 m³/hr to USP and Ph. Eur. specifications, and HVAC engineered for cGMP environmental controls across all classified spaces.

• Procurement and Supply Chain Support

We executed a multi-geography procurement programme across 78 critical vendors. Glass-lined and Hastelloy reactors and process vessels were sourced from established European specialists; agitated nutsche filter dryers and centrifuges from German and Italian OEMs with documented USFDA-approved API installations; spray dryers and fluidised bed dryers from European and Indian suppliers; solvent recovery distillation columns from a Swiss process engineering specialist; the multi-effect evaporator and mechanical vapour recompression effluent treatment system from a European water-technology integrator. Civil, MEP, and clean utility packages were awarded to qualified Indian contractors with documented USFDA-grade API project track records.

Key Starting Material sourcing was structured to maximise PLI Domestic Value Addition: long-term supply agreements were established with seven Indian intermediate manufacturers covering 14 critical upstream intermediates, with deliberate selection of Indian sources over historically-imported Chinese suppliers where capacity and quality permitted. Where intermediates were not yet available domestically at required scale, structured technology-transfer agreements with Indian KSM specialists were initiated to localise production over the PLI scheme tenure. Solvent sourcing combined Indian petrochemical refinery production for high-volume solvents with European specialty sources for chiral and high-purity grades. Vendor qualification protocols included supplier audits, Certificate of Analysis review against USP/EP specifications, full elemental impurity and residual solvent characterisation, and PLI DVA documentation aligning every procurement decision to the scheme's Year-by-Year domestic content milestones.

• Project Execution and Site Management

Our turnkey project management delivered 32 months from groundbreaking to first commercial batch, coordinating civil construction, mechanical erection, clean utility installation, technology transfer for each of the 12 APIs, and integrated commissioning across the six campaign blocks. We managed construction of the production blocks (each 4,800 sq.m), the central solvent recovery and effluent treatment complex (8,400 sq.m), the QC and microbiology laboratories (3,200 sq.m), the API and KSM warehouse with controlled-substance and refrigerated storage, and the Bulk Drug Park common-utilities interface. Phased commissioning ran Block 6 (hydrogenation and high-pressure reactions) first as the highest-risk technical block, followed by Block 5 (KSM and intermediates) feeding the four campaign API blocks in parallel.

Installation supervision ensured pharmaceutical-grade specifications: orbital-welded high-purity stainless steel piping for all Purified Water, validated electropolished reactor surfaces with documented surface roughness below Ra 0.6 micrometres, full intrinsic-safety classification across solvent-handling areas under ATEX-equivalent Indian standards, and environmental monitoring with 196 fixed sensors logging temperature, humidity, particle count, and pressure differential across all classified spaces. Multi-vendor coordination across European, Indian, and Indian-European hybrid contractors required a 28-strong owner's engineering team supplemented by 12 Indian-European resident chemists embedded across the six blocks for technology-transfer validation. Pre-Approval Inspection readiness was driven through three sequential mock-PAI campaigns conducted by an independent consulting firm prior to the actual USFDA inspection in month 16.

• Compliance, Quality and Sustainability

IMARC led certification readiness across USFDA cGMP, EU EMA Ph. Eur. inspection, WHO Prequalification, CDSCO Manufacturing Licence, and ISO 9001, ISO 14001, ISO 45001, and ISO 50001 management systems. Across the first 18 months of operations, the facility achieved 9 USFDA Drug Master File approvals and 7 EU EMA Active Substance Master File approvals across the targeted 12 APIs, with the remaining filings progressing through agency review. We implemented an integrated quality system with inline NIR and HPLC analysis at critical process points, full electronic batch records compliant with 21 CFR Part 11 and EU Annex 11, and lot-level traceability from KSM intake through to finished API release.

Environmental compliance covered Andhra Pradesh Pollution Control Board Consent to Operate, Central Ground Water Authority clearance, Hazardous Waste Authorisation for spent solvents and reaction by-products (handled through dedicated regeneration, incineration, and licensed offsite disposal streams), and Extended Producer Responsibility commitments. Zero-liquid-discharge was demonstrated through annual compliance audits, with 100 percent of treated effluent reused as cooling tower make-up or process water. The facility achieved IGBC Gold certification through 4 MW captive solar, solvent recovery at 94 percent saving approximately INR 38 Crore annually in solvent purchase costs, heat recovery from distillation reboilers and condensers, and 26 percent lower process energy intensity versus the Chinese API industry benchmark per third-party LCA study.

Final Results

Operational Performance

The facility achieved mechanical completion in 32 months with the first commercial API batch released in month 33. Full 480 MT per annum nameplate capacity across the 12 APIs was reached at 86 percent utilisation by month 18 of operations, with first-pass batch success rate of 96.8 percent across the qualified product portfolio. USFDA Pre-Approval Inspection passed in month 16 with zero critical observations; EU EMA inspection in month 19; and WHO Prequalification certification in month 22. Cumulative quality performance across the first operational year recorded zero batch recalls, zero Out-of-Specification investigations escalated to regulatory authorities, and full lot-genealogy traceability across all 348 commercial batches released.

Financial Outcomes

Final CapEx of INR 1,840 Crore delivered 4.2 percent savings against the INR 1,920 Crore budget through optimised civil packaging, deliberate Indian-fabrication leverage for vessels and structurals, and disciplined solvent-recovery integration that reduced upstream solvent procurement requirements. The Andhra Pradesh Bulk Drug Park capital subsidy of INR 192 Crore was disbursed against construction milestones, and PLI Bulk Drugs Tranche 1 and 2 disbursements were secured against year-1 and year-2 production milestones. Year-2 revenue of INR 2,340 Crore was generated at an EBITDA margin of 22 percent — comfortably above the regional API industry benchmark — supported by direct supply to Indian formulators and regulated-market export pricing.

Market Access

Drug Master File approvals advanced rapidly: 9 USFDA DMFs and 7 EU EMA Active Substance Master Files were approved across the 12 API portfolio within the first 18 months of operations, alongside Japanese PMDA filings progressing for three high-priority APIs. Long-term supply contracts were signed with six major Indian formulators covering committed annual offtake of approximately 280 MT, with parallel regulated-market export contracts secured with three US generic majors and two European specialty formulators. The facility substituted approximately 36 percent of Indian import dependence across the 12 targeted KSMs, with cumulative import substitution rising as Phase 2 fermentation capacity comes onstream.

Sustainability Impact

Our integrated design — combining 4 MW captive solar (12,400 panels) covering 5-6% percent of facility energy demand, heat recovery from solvent recovery distillation reboilers and condensers, mechanical vapour recompression on effluent evaporation reducing energy load by 38 percent versus conventional multi-effect, variable-frequency drives across all motor loads, and disciplined LED lighting throughout — achieves 26 percent lower process energy intensity versus the Chinese API industry benchmark, saving INR 28 Crore annually in energy operating cost. Solvent recovery at 94 percent across all major process solvents saves an additional INR 38 Crore per year in solvent purchase costs and substantially reduces VOC emissions. Zero-liquid-discharge was demonstrated and maintained throughout the first operational year, with annual third-party audits validating 100 percent effluent reuse.

Strategic Impact

The project established one of India's first integrated multi-purpose API facilities operating at PLI-aligned scale within the approved Bulk Drug Park framework, demonstrating the operational viability of India's strategic API localisation thesis at commercial scale. Year-2 revenue of INR 2,340 Crore, 96.8 percent first-pass batch success, USFDA Pre-Approval Inspection completion with zero critical observations, and the 36 percent import substitution share for the targeted 12 KSMs led the client to approve Phase 2 expansion comprising a dedicated penicillin G fermentation facility and a vitamin synthesis line — both targeted at deeper KSM-level localisation under the PLI scheme's fermentation category. IMARC Engineering's end-to-end EPCM advisory — uniquely combining multi-purpose API process engineering, PLI scheme navigation, USFDA cGMP commissioning, and Bulk Drug Park common-utilities integration — enabled the client to anchor a strategically critical Indian industrial asset in a sector where execution complexity, regulatory rigour, and import-supplier disruption risk had previously deterred greenfield investment at this scale.